Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment [PDF]
BMC GastroenterologyAim The aim of this study was to explore the accuracy of the diagnosis of gastro-esophageal reflux disease (GERD) through tegoprazan treatment trials, and to analyze factors that may influence test accuracy.
Peiwen Dong +12 more
doaj +2 more sources
Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2018 Tegoprazan [(S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide], a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging from 0.29 to 0.52 μM, while that ...
Nobuyuki, Takahashi, Yukinori, Take
openaire +4 more sources
Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males [PDF]
Clinical and Translational ScienceFexuprazan, a novel potassium‐competitive acid blocker, is expected to be used for the prevention of nonsteroidal anti‐inflammatory drugs (NSAIDs) induced ulcer. This study aimed to evaluate pharmacokinetic (PK) interactions between fexuprazan and NSAIDs
Heejae Won +8 more
doaj +2 more sources
A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis [PDF]
JGH OpenIntroduction Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of healed erosive esophagitis (EE). It is unknown whether potassium‐competitive acid blockers (PCABs) are more efficacious and safer than PPIs.
Daniel M Simadibrata +6 more
doaj +2 more sources
Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy [PDF]
Scientific ReportsAs the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and
Hyun Jung Lee +5 more
doaj +2 more sources
A case of toxic epidermal necrolysis associated with vonoprazan, a potassium-competitive acid blocker [PDF]
JAAD Case ReportsDonna Pham, MS +3 more
doaj +2 more sources
A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. [PDF]
J Gastroenterol Hepatol, 2022 Simadibrata DM, Syam AF, Lee YY.
europepmc +2 more sources
Size reduction of gastric fundic gland polyposis by de‐escalation of acid‐suppressive therapy
DEN Open, 2023 The patient, a 73‐year‐old woman, had been taking acid‐suppressive therapy for refractory reflux esophagitis for 10 years. A potassium‐competitive acid blocker was administered to strengthen acid‐suppressive therapy for worsening symptoms of ...
Akira Kanamori +14 more
doaj +1 more source
Potassium-competitive acid blockers and gastroesophageal reflux disease
World Journal of Gastroenterology, 2022 Proton pump inhibitors (PPIs), the most commonly used antisecretory medi-cations in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy.
Leowattana, Wattana +1 more
openaire +2 more sources
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan. [PDF]
Intern Med, 2022 Okamoto M, Wakunami Y, Hashimoto K.
europepmc +2 more sources